前苏联专利SU1455999A3 Method of producing digitalis antibodies

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
This invention relates to the field of immunochemistry and relates to a method for producing digitalis antibodies. The aim of the invention is to increase the specificity of antibodies and the degree of purification from endotoxins. The method is carried out by obtaining a specific anti-shortblade, by the release of gamma globulin, which is derived from an immunosorbent representing porous glass, or silica gel or alumina with a pore volume of 1–20, in which digitoxalaldehyde is bound and cleaved by a flow of hemorrhage, hepaths, to the hepaths, to the hepatitis, to the hepatitis, to the hemorrhagic hemorrhagic). At the same time, digitalis antibodies are eluted from the immunosorbent with aqueous acid after preliminary washing with a solution of pH 6.0-7.5. The obtained antibodies are further purified by gel chromatography on sephacrip 200 and ion exchange chromatography on DEAE cellulose DE-32. The specificity of the antibodies obtained is increased by 18-20%. ABOUT)
公开号:SU1455999A3
申请号:SU843817568
申请日:1984-11-23
公开日:1989-01-30
发明作者:Бац Ханс-Георг；Юнгфер Херберт；Ленц Хельмут；Бедер Альберт
申请人:Берингер Маннхайм Гмбх (Фирма)；
IPC主号:

专利说明:

.one
This invention relates to medicine, specifically to immunochemistry, and concerns a method for producing digitalis antibodies.
The aim of the invention is to increase the specificity of antibodies and the degree of purification from endotoxins.
Example 1. Getting sheep antidigoxin serum.
Immunogen.
Digoxin-glutarip-o-oxysuccinin-10 MFA in aqueous solution is introduced into interaction with protein, especially with bovine globulin or edestin (protein from hemp seeds). After an excess of digo-xenin derivative has been separated, several digoxin molecules per protein molecule with terminal digitotox are linked via a glutaryl chain to the protein.
: Immunization
0.5 mg of digoxin immunogen in Freund's complete adnovant are administered intracutaneously to healthy sheep weighing at least 45 kg. First through each
2 weeks and then every 4 weeks, the immunogen in the same carrier is reintroduced intramuscularly and subcutaneously to enhance the immunity response. After 2-4 months, a serum titer of animals is achieved 1 mg of digoxin-specific immunoglobulin / un,
Selection of short-cut, analytics, pooling.
4i SP
ate
with so with so

cm
In healthy animals that have reached the specified titer when taking a sample, for a minimum of one year “it is possible to take blood from the cervical vein weekly. In sampling samples, the titer is constantly monitored using a radioimmune test or using an enzyme-immune test. Binding constants are also determined in sample samples by evaluating the binding of radioactively labeled 1 digoxin by determined dilutions of antiserum Samples. In accordance with the literature, values of 5x10 -5x10 l / mol Dp are obtained in order to maintain, on an occasion, insignificant fluctuations
the composition used to isolate the MB fragments of antisera, amounts of 20-50 liters are collected from individual selections of several sheep.
2c Preparation of immunosorbent.
Amino group containing glass.
Dp removes fine particles and comes with ethanol, water, ethanol, then
940 g of porous glass with a surface of 10 m / g are treated with ultrasound in aqueous suspension, then heated for 3 hours in 65% nitric acid at 80–90 ° С. 1 | after acid was removed from the glass, it was dried at 150 ° C. Purified glass Was stirred under reflux in 2.7 g of anhydrous dimethyl sulfoxide with 300 ml of 3- (three-ethoxy silyl) propylamine for 20 hours at 85 ° C. Excess silylation is washed away with isopropanol and the aminated Nano glass is dried again (60 ° C, slight vacuum). Output Approximately 1.8 g of aminopropyl glass (750 g).
Oxidation of digitoxin.
6 g of digitoxin in 450 ml of the mixture; tanol with water (2: 1) is subjected to isoimmunication with a stoichiometrically equal amount of sodium peristate. (1.7 g) for 20 hours at room temperature. The insoluble precipitate is filtered off and removed. The supernatant is evaporated to dryness on a rotary evaporator. The residue is taken up with 2x100 ml of water, then dried in vacuo over calcium chloride. By 4-5 g xina.
Adsorbent digitoxin-glass.
4.5 g of oxidized digitoxin are dissolved in 2.25 L of ethanol mixture
dried in the weak. Output 1.8 g of immunosorbent.
Preparation of immunosorbent for direct use.
30 The sorbent is suspended in buffer A (50 mmol phosphate with pH-7.0 / 0.15 M sodium chloride / 0.1% sodium azide), fed into a glass frit glass and washed successively
2g with a solution of 0.5 M chloride over three and 0.05% Tween-20, bidistilled water and 1 M propionic acid, finally, is equilibrated with buffer A. The used benturizer is regenerated by rinsing with 1 M propionic acid, after which it is stored. nt in buffer A with 4 Co Sorbent can be used repeatedly. Immediately before use
45 fresh sorbent pre-washed
Zo Obtaining sheep anti-digox-FAB fragments.
Used solutions. Sterilized
5Q in autoclaves or by membrane filtration. Used to prepare solutions of water that is pyrogen-free due to the distillation of the tank,
devices, as well as other auxiliary-oxidized digital gg materials (for example, materials
for chromatography) are pyrogen-free by heating or by treatment with 0.3 M sodium hydroxide.
with water (2: 1), mixed with 750 g of aminopropyl glass and slowly stirred for 20 hours at room temperature. The glass is filtered. Digitoxin is determined by measuring the extinction in the UV region (260 nm) and using the data obtained, the amount of fixed 0 digitoxin is calculated (set value: 3 mg digitoxin per ml of glass volume). 4 g of sodium borohydrate is dissolved in
1 l of bidistilled water, diluted with 2 l of ethanol and fed to a modified digitoxin-finished glass. With repeated interruptions during
The pH was adjusted to 7.0-7.4 at room temperature by 2 hours by adding 2 mM hydrochloric acid. Wherein
0, a fixed degree of fixation is reported to fixed to glass first via labile bonds of the type of Schiff's base to digitoxin. The resulting immunosorbent is thoroughly washed and dried in a weak one. Output 1.8 g of immunosorbent.
Preparation of immunosorbent for direct use.
30 The sorbent is suspended in buffer A (50 mmol of phosphate with a pH of 7.0 / 0.15 M sodium chloride / 0.1% sodium azide is fed to a fritted glass column and washed successively
2g with a solution of 0.5 M chloride on three and 0.05% tween-20, bidistilled water and 1 M propionic acid, finally, is equilibrated with buffer A. The used immunosorbent is regenerated by washing with 1 M propionic acid, after which xrn in buffer A with 4 Co Sorbent can be used repeatedly. Immediately before use
45 fresh sorbent pre-washed
Zo Obtaining sheep anti-digox-FAB fragments.
Used solutions. Sterilized
5Q in autoclaves or by membrane filtration. Used to prepare solutions of water that is pyrogen-free due to the distillation of the tank,
800 ml is concentrated by ultrafiltration to a volume of 150 ml, then dialyzed against buffer (15 Mm phosphate, pH 7.5 / 0.15 M sodium chloride).
Chromatography is repeated for the second portion of the FAB lyophilisate on the same column. Both chromatographic portions are again combined for further use. Intermediate storage of the first part is carried out at -20 ° C.
Passing through the ion exchanger ().
400 ml of DE-52 cellulose (pretreated with 0.5N HCl and 0.5N NaOH to sterilize and release pyrogen) are fed to the column and equilibrated with 10 mmol of phosphate buffer at pH-7.1. FAV-protein with a gorge. stages by ultrafiltration are adjusted to a concentration of 50 mg / ml and then passed through a column. The FAB protein emerges almost immediately, traces of foreign proteins (e.g. albumin, PS-fragments, etc., etc.) are retained. FAB protein is collected in the runoff, if necessary, concentrated by ultrafiltration to 15–20 mg of protein / ml, the pH is adjusted to 7.0–7.1 on the electrode and filtered sterilely through a membrane filter with a value of 0 2 mmk. The final yield of 5-6 g of sheep anti.cytoxin FAB. The sterile filtered target product is poured into glass containers in the absence of microorganisms and stored at.
The digitalis antibodies obtained in Example 1 contain 84.8 mg of proteins in an ampoule and have a binding capacity of 0.013 mg of digoxin / mg of FAB fragments. In addition, the content of endotoxin (protein contaminant that can cause fever and allergic effects) in a vial is 0.22 units. The digitalis produced in a known manner have the following qualities: protein content 43.8 mg; a binding capacity of 0.011 mg of digoxin / MFBB fragments; the content of endotoxin in the ampoule 12,8o
Comparison of data on coupling capacity, which is a measure of the specificity of digitalis antibodies, suggests that the resulting
five
0
five
0
five
0
five
0
five
In this way, antibodies have a specificity that is 18.2% greater than that obtained by a known method.
In addition, obtained by the proposed method, the antibodies also have a higher degree of purity, as evidenced by the comparison of data on the content of endotoxin (see table).
Example 2. Example 1 is repeated, with the only difference that section 2 uses silica gel with a surface of 20. In this case, purification of the initial silica gel is carried out by suspending three times in 2 liters of water, which is weakly acidified with nitric acid, with subsequent decanting of small components at each stage. The resulting digitalis antibodies have the same quality as the antibodies of example 1.
Example 3 о Example 1 is repeated, with the only difference that in section 2 an alumina gel with a surface of 1 m / g is used. In this case, the initial sklicagel is cleaned by suspending water three times in 2 liters of water, weakly acidified with nitric acid, followed by decanting of small components at each stage. In addition, immunosorbent used in section 3 in the amount of 5.0 liters. The resulting digitalis antibodies have the same qualities as the antibodies of example 1.
Example 4: Example 1 is repeated with the only difference that the elution stage of the FAB fragments is carried out: a) 3 mmol of aqueous phosphoric acid or b) 5 mmol of aqueous acetic acid, or c) 2 mmol of aqueous sulfuric acid.
The resulting digitalis antibodies have the same qualities as the antibodies of example 1.
Example 5. Example 1 is repeated, but as a solvent for adsorption and cleavage with papain, for example, only buffer solution of sodium acetate and acetic acid (0.5 M, pH 6.0) is used. Papain digestion is carried out in that a solution of 240 mg of papain in 2 liters of this buffer is fed directly to the column, the liquid is passed in approximately 30 minutes, and immediately after this the passage is stopped and the solution is charged for another 5 hours. Nepa5
Pre-cleaning of sheep anti-digoxin discharger,
30 liters of antiseutroses are stirred for 1 hour at room temperature along with 300 g of an aerosol to remove lipoproteins. After separating the aerosol by centrifuging from the supernatant cooled to A ° C by adding ammonium sulfate to a concentration of 1.8 M, gamma globulins are precipitated. By centrifugation, the precipitate is collected, dissolved in a solution of 0.15 M sodium chloride (0.1% azide) and dialyzed against a buffer (15 mM phosphate, pH 7.1 / 50 mM sodium chloride / O, 002% gibitan) at. Dialysate is fed to a 16.2 liter column with diethylaminocellulose (DE-52) and eluted with a buffer of the same composition as dialysis buffer. The protein exiting from the column with this buffer is the immunoglobulin fraction from a sheep's anti-digoxin fold that is tapped at the end of the FAB fragments. The protein yield is 500-700 g. The content of digoxin-specific antibodies is approximately 80-90% of the original serum titer.
Specific adsorption.
250 g of immunoglobulin fraction in 10 l of a solution containing digoxin-specific immunoglobulin equal to 15 g, are fed into the buffer 50 mels of phosphate / 0.15 M: -sodium sodium / 0, 002% gibitak (pH 7.0, buffer B. This solution is pumped through a column filled with 2.4 liters of the indicated immunosorbent at room temperature for about 2 hours. Specific immunoglobulin fragments are 90% bound to a with absorbent. The adsorbent is washed with buffer B, to which is added another 0.35 M sodium chloride and p, twin-205 then equilibrated with buffer B (85 mmol osfata, pH 7.0 / 0.15 moles of sodium chloride / 2 mM ethylenediamine tetraacetic acid / 10 mM tsiste- apos / 0.01% gibitan /, which is suitable for subsequent cleavage papaynom.
Enzyme fragmentation.
The adsorbent loaded with digoxin-specific immunoglobulin is immediately transferred to glass containers and mixed with 240 mg of papain.
dissolved in 2 l of buffer C. When i, slowly mixing with; blade metal mixers are incubated for 255 minutes at 37 ° C. By measuring samples of the supernatant of the suspension-adsorbent in a UV photometer (280 nm) at different times during incubation, one can follow Q for the kinetics of PS protein release and the formation of FAB fragments , At the end of the incubation. The adsorbent is again loaded onto the column and washed with buffer B. To saturate
15 free H-groups from the papain cleavage process in the presence of cysteine, the adsorbent is buffered (75 mM phosphate, pH 7.5 / 0.15 M sodium chloride / 0.01% gibitan),
20 to which 10 mM of iodoacetate is added. The iodoacetamide buffer is left for 2 hours at room temperature in contact with the adsorbent. Then using a solution of 0.15 mol of chloride
25 sodium / 0.01% gibitan wash away excess iodoacetamide and prepare an adsorbent for elution with 30 mM sodium chloride solution.
30 Eluation (at room temperature).
For elution of specific FAB fragments is passed through the column with 3 mM aqueous hydrochloric acid, FAB protein in the effluent from the column is detected by measuring UV adsorption (280 nm) and collected. 5-7 l of solution containing about 11 g of protein are concentrated by ultrafiltration
Q to a volume of 200-250 ml, then immediately lyophilized „
Gel permeation chromatography ().
1 m column filled with 7.5 l
g of sephacryl S-200 and equilibrated with buffer (5 mM phosphate, 0 / 0.5 M sodium chloride / 0.002% gibitan), Approximately 5 g of FAB-lysing solution is dissolved in 110 M equilibration buffer35
50
55
ra and served on the column. By detecting UV absorption in the eluate, a FAB peak with a molecular weight of 50,000 is established and collected. The yield of approximately 3.75 g of gel-chromatographically homogeneous protein. The remaining immunoglobulin fractions, high molecular weight FAB aggregates and lower molecular weight fractions are separated. Approximately 70015 FAB solution
20
After that, it is washed
4L papain free buffer solution and FLB fragments washed out
5 mmol of aqueous acetic acid according to example 4. The results correspond to the results of example 1.
Example 6. The reaction of Example 1 is repeated with the only difference that sodium chloride, added to the buffer solution C, is replaced with 0.2 mol of aluminum carbonate. In addition, gel-enzyme chromatography on sefrile S-200 is replaced by chromatography on Sephadex 1 25 M (Phaunacia Fine Chemicale) o In this case, the results also correspond to the results of Example 1, proving that it is not an adsorption agent, but a type of cleavage There is also no corresponding antibody effect (there are no differences if the cleavage is carried out not in a separate vessel, but directly in the column.
Example 7 Example 5, 25 is repeated. The sodium phosphate buffer (0.5 M, pH-7.5) is used as a solvent for adsorption and cleavage of papain and a strain gel with a specific surface area of 1.0 m is used as an adsorbing agent. / g
Cleavage of papain is carried out in that a solution of 240 g of papain in 2 liters of this buffer is applied directly to the column, and the liquid flows for about 30 minutes and then interrupts its flow and the solution is left on the column for another 5 hours. Then, rinse with 4 L of papain-free buffer and the FAB fragments were extracted with 5 mmol of aqueous acetic acid as in Example 46, the Results correspond to Example 1,
Example 8 The reaction of Example 1 is repeated with the deviation that spruce-fermentation chromatography exists on almini oxide gel with a specific surface area of 20. the phosphate buffer solution is set, 0, Also with the results of the results corresponding to example 1,
The proposed method allows ovysit 18-20% of the specificity
thirty
35
40
45
50
five
0
d
five

权利要求:
Claims (1)
[1]
antibodies and significantly increase the degree of removal of endotoxin 5
The method of producing digitalis antibodies, including immunization of mammals with digoxin-protein antigen, the distribution of gamma globulin, cleavage with papain, the dissemination of FAB fragments on the immunosorbent using rinse and elution, gel filtration and ion exchange chromatography, a graduate template, a graduate, a graduate, a graduate, a graduate, a graduate, a graduate, antibodies and the degree of purification from endotoxins that antibodies adsorb on the immunosorbent, consisting of porous glass, or silica gel, or oxide with a pore volume of 1-20, in which the digitoxaldehyde is captured, the antibodies are cleaved on an adsorbent, the wash is performed with a buffer solution of pH 6.0-7.5, and the antibodies are eluted with aqueous acid.

类似技术:

公开号 | 公开日 | 专利标题

SU1455999A3|1989-01-30|Method of producing digitalis antibodies

US4606825A|1986-08-19|Purification of immunoglobulin G

WO1989012065A1|1989-12-14|Chromatographic separation of plasma proteins

JPH06107561A|1994-04-19|Preparation of intravenous compatible immunoglobulin-g-formulation

WO1992003736A1|1992-03-05|Assaying agent for endotoxin

SU1523046A3|1989-11-15|Method of purifying human beta-interferon

US4468345A|1984-08-28|Protein |, a process for concentrating and isolating it and its use

Mahieu et al.1973|Primary structure of a small glycopeptide isolated from human glomerular basement membrane and carrying a major antigenic site

US4746731A|1988-05-24|Isolated tissue protein PP18

US4368148A|1983-01-11|Protein PP9, process for its enrichment and its isolation and its use

CA1101847A|1981-05-26|Process for the concentration of a placenta-specific glycoprotein

Poulik et al.1983|Post-gamma globulin. II. Radioimmunoassay determination of levels of post-gamma globulin and β2-microglobulin

US4325866A|1982-04-20|Protein, PP11, a process for its preparation and its use

US4592863A|1986-06-03|Protein PP20, a process for obtaining it, and its use

US4264449A|1981-04-28|Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith

CA1085292A|1980-09-09|Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith

US4594328A|1986-06-10|Tissue protein PP21, a process for obtaining it and its use

US4599318A|1986-07-08|Tissue protein PP19, a process for obtaining it, and its use

US4309339A|1982-01-05|Leucine-rich 3,1-S-α2 -glycoprotein, process for isolating it and its use

Lundwall et al.1981|Isolation of component C4 of human complement and its polypeptide chains

US4656025A|1987-04-07|Quantitative screening assay of tumor globulin from gastric juice

MacKAY et al.1982|Quantitative recovery, selective removal and one‐step purification of human parotid and leukemic lysozymes by immunoadsorption

JPH10111291A|1998-04-28|Method for diagnosis of iga nephropathy

Biewenga et al.1982|Binding of human IgA myeloma proteins to protein A. Evidence for different binding mechanisms

JPH0768269B2|1995-07-26|Method for purifying C-reactive protein

同族专利:

公开号 | 公开日

EP0143413A3|1988-07-20|

CA1242393A|1988-09-27|

JPH0324480B2|1991-04-03|

US4742159A|1988-05-03|

EP0143413B1|1991-06-05|

AT64141T|1991-06-15|

JPS60132922A|1985-07-16|

DE3484673D1|1991-07-11|

DE3342870A1|1985-06-05|

ES8600770A1|1985-11-01|

EP0143413A2|1985-06-05|

ES537909A0|1985-11-01|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

US3790475A|1972-03-27|1974-02-05|Corning Glass Works|Porous glass support material|

US4039652A|1973-10-11|1977-08-02|Miles Laboratories, Inc.|Column method of immunoassay employing an immobilized binding partner|

US4081245A|1976-05-03|1978-03-28|Beckman Instruments, Inc.|Immunoassay procedure employing novel immunochemical composites|

US4081246A|1976-05-03|1978-03-28|Beckman Instruments, Inc.|Solid phase column immunoassay procedure employing novel immunochemical composites|

US4232004A|1977-09-21|1980-11-04|American National Red Cross|Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith|

US4434234A|1981-04-02|1984-02-28|The Upjohn Company|Method and kit for silver staining substances supported in matrix|US4849352A|1984-10-09|1989-07-18|Sullivan John B|Antibody purification process|

US4841024A|1986-09-15|1989-06-20|Becton Dickinson And Company|Purification of antibodies|

US4814433A|1987-09-16|1989-03-21|Miles Inc.|Method for obtaining a papain-free antibody fragment preparation|

US5328834A|1989-09-08|1994-07-12|Unisyn Technologies, Inc.|Method for preparing immunoglobulin fragments|

EP0916678A3|1993-06-03|1999-05-26|Therapeutic Antibodies Inc.|Method of clotting blood|

WO2001089602A1|2000-05-25|2001-11-29|Kaneka Corporation|Adsorbent for cardiac glycoside, and method and device for adsorbing and removing cardiac glycoside|

FR2810667B1|2000-06-23|2004-09-03|Warner Lambert Co|PROCESS FOR ISOLATING AND PURIFYING PROTEIN, AND PROTEIN OBTAINED|

US6802966B2|2001-08-14|2004-10-12|W. R. Grace & Co. Conn.|Solid compositions for selective adsorption from complex mixtures|

US6987079B2|2001-08-14|2006-01-17|W.R. Grace & Co.-Conn.|Supported catalyst systems|

US7794716B2|2002-07-25|2010-09-14|Glenveigh Pharmaceuticals, Llc|Antibody composition and passive immunization against pregnancy-induced hypertension|

US20080003230A1|2006-07-03|2008-01-03|Adair Charles D|Composition for modulating the expression of cell adhesion molecules|

CA2745111A1|2008-12-03|2010-06-10|Research Development Foundation|Modulation of olfml-3 mediated angiogenesis|

CA2888345C|2012-10-24|2020-04-21|Research Development Foundation|Jam-c antibodies and methods for treatment of cancer|

EP3036005A4|2013-08-21|2017-04-26|The Board Of Regents Of The University Of Texas System|Compositions and methods for targeting connexin hemichannels|

CN108925136B|2015-12-02|2022-02-01|斯特赛恩斯公司|Antibodies specific for glycosylated BTLA |

US10875920B2|2015-12-02|2020-12-29|Stcube & Co., Inc.|Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof|

WO2017147561A1|2016-02-26|2017-08-31|The Board Of Regents Of The University Of Texas System|CONNEXIN43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF|

WO2017172518A1|2016-03-29|2017-10-05|Stcube, Inc.|Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof|

US11046782B2|2016-03-30|2021-06-29|Musc Foundation For Research Development|Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominantand for providing effective immunotherapy alone or in combination|

CN109715666A|2016-07-20|2019-05-03|斯特库比股份有限公司|The combined therapy of cancer treatment method and the antibody using combination glycosylation PD-L1|

EP3630835A1|2017-05-31|2020-04-08|STCube & Co., Inc.|Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof|

JP2020522512A|2017-05-31|2020-07-30|ストキューブアンドシーオー．，インコーポレイテッド|Method of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1|

KR20200026209A|2017-06-06|2020-03-10|주식회사 에스티큐브앤컴퍼니|How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand|

WO2021062323A1|2019-09-26|2021-04-01|Stcube & Co.|Antibodies specific to glycosylated ctla-4 and methods of use thereof|

WO2021072277A1|2019-10-09|2021-04-15|Stcube & Co.|Antibodies specific to glycosylated lag3 and methods of use thereof|

WO2021167908A1|2020-02-17|2021-08-26|Board Of Regents, The University Of Texas System|Methods for expansion of tumor infiltrating lymphocytes and use thereof|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

DE19833342870|DE3342870A1|1983-11-26|1983-11-26|DIGITALIS ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR THE THERAPY OF DIGITALIS INTOXICATIONS|

[返回顶部]